Author

J. I. Everitt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. A. Sag· 1 shared A. Agarwal· 1 shared A. Lazarides· 1 shared B. Crouch· 1 shared C. Eward· 1 shared C. M. Counter· 1 shared C. Nief· 1 shared C. T. Lam· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Sag

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

p53 dosage impedes KrasG12D- and KrasQ61R-mediated tumorigenesis

O. Le Roux, J. I. Everitt, C. M. Counter

The paper shows that increasing p53 dosage reduces tumor number and grade across multiple organs, regardless of Kras mutation type, and extends lifespan in a KrasG12D model.

bioRxiv · Sep 17, 2023Cancer Biology

Irgm proteins attenuate inflammatory disease in mouse models of genital Chlamydia infection

J. Dockterman, J. I. Everitt, G. Wallace, J. Coers

This paper shows that Irgm proteins in mice reduce inflammation and scarring during Chlamydia infection without affecting bacterial levels, highlighting their role in disease tolerance.

bioRxiv · Jul 6, 2022 · PreprintImmunology

Lung-selective Cas13d-based nanotherapy inhibits lethal SARS-CoV-2 infection by targeting host protease Ctsl

Z. Cui, C. Zeng, F. Huang, F. Yuan, J. Yan, Y. Zhao, J. Huang, H. F. Staats, J. I. Everitt, G. D. Sempowski, H. Wang, Y. Dong, S.-L. Liu, Q. Wang

This paper develops a lung-selective Cas13d-based nanotherapy targeting Ctsl to inhibit SARS-CoV-2 infection, showing improved survival and reduced viral burden in mice.

bioRxiv · Oct 3, 2021 · PreprintMicrobiology

A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma

J. Somarelli, G. Rupprecht, E. Altunel, E. Flamant, S. R. Rao, D. Sivaraj, A. Lazarides, S. Hoskinson, M. Sheth, S. Cheng, S. Y. Kim, K. Ware, A. Agarwal, M. Cullen, L. Selmic, , D. Hsu

This study develops a cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma, finding that dual inhibition of proteasome and CRM1 pathways induces synergistic cytotoxicity.

bioRxiv · Oct 19, 2020Cancer Biology

Polymer-assisted intratumoral delivery of ethanol: Preclinical investigation of safety and efficacy in a murine breast cancer model

C. Nief, R. Morhard, E. Chelales, D. Adrianzen Alvarez, I. Bourla, C. T. Lam, B. Crouch, A. A. Sag, J. L. Mueller, D. Katz, M. W. Dewhirst, J. I. Everitt, N. Ramanujam

This study evaluates a polymer-assisted ethanol ablation method in a murine breast cancer model, finding it safer and more effective than conventional ethanol ablation.

bioRxiv · May 29, 2020Cancer Biology